TDP-43 activates microglia through NF-κB and NLRP3 inflammasome - PubMed (original) (raw)
TDP-43 activates microglia through NF-κB and NLRP3 inflammasome
Weihua Zhao et al. Exp Neurol. 2015 Nov.
Abstract
Transactive response DNA-binding protein-43 (TDP-43) is a multifunctional nucleic acid binding protein present in ubiquitinated inclusions in tissues of patients with amyotrophic lateral sclerosis (ALS) and fronto-temporal lobar degeneration (FTLD). The ALS-associated mutations in the glycine-rich C-terminal domain of TDP-43 established a causal link between TDP-43 and disease, and conferred both loss- and gain-of-function properties in neurons. Since it has not been established whether these intra-neuronal changes are sufficient to cause ALS or whether non-cell autonomous neuronal-glial signaling could be involved, we investigated the extracellular effects of TDP-43 proteins on microglial activation and motoneuron toxicity. Wild-type, truncated 25kD C-terminal fragments, or mutant forms of TDP-43 all activated microglia and upregulated NOX2, TNF-α, and IL-1β, with WT forms being significantly less effective in activating microglia. This response to TDP-43 was mediated by its interaction with the microglial surface CD14 receptor and subsequent stimulation of the NF-κB and AP-1 pathways, as well as the intracellular inflammasome. At the cell surface, CD14 blocking antibodies suppressed microglial NF-κB activation and proinflammatory cytokine production mediated by TDP-43. Intracellularly, the NLRP3 inflammasome was induced and functional caspase-1 was produced augmenting the release of mature IL-1β. Further, TDP-43-mediated activation of microglia caused a proinflammatory cascade that was toxic to motoneurons. In the absence of microglia, TDP-43 was not toxic to motoneurons. The ability of TDP-43 to promote CD14-mediated activation of microglial NF-κB and AP-1 pathways, as well as the NLRP3 inflammasome, suggests the involvement of a non-cell autonomous proinflammatory signaling that enhances motoneuron injury, and may offer novel therapeutic targets in ALS.
Keywords: CD14; Microglia; NF-κB; NLRP3 inflammasome; TDP-43.
Copyright © 2015 Elsevier Inc. All rights reserved.
Similar articles
- NLRP3 inflammasome is expressed by astrocytes in the SOD1 mouse model of ALS and in human sporadic ALS patients.
Johann S, Heitzer M, Kanagaratnam M, Goswami A, Rizo T, Weis J, Troost D, Beyer C. Johann S, et al. Glia. 2015 Dec;63(12):2260-73. doi: 10.1002/glia.22891. Epub 2015 Jul 21. Glia. 2015. PMID: 26200799 - Aloe vera downregulates LPS-induced inflammatory cytokine production and expression of NLRP3 inflammasome in human macrophages.
Budai MM, Varga A, Milesz S, Tőzsér J, Benkő S. Budai MM, et al. Mol Immunol. 2013 Dec;56(4):471-9. doi: 10.1016/j.molimm.2013.05.005. Epub 2013 Aug 1. Mol Immunol. 2013. PMID: 23911403 - The microglial NLRP3 inflammasome is activated by amyotrophic lateral sclerosis proteins.
Deora V, Lee JD, Albornoz EA, McAlary L, Jagaraj CJ, Robertson AAB, Atkin JD, Cooper MA, Schroder K, Yerbury JJ, Gordon R, Woodruff TM. Deora V, et al. Glia. 2020 Feb;68(2):407-421. doi: 10.1002/glia.23728. Epub 2019 Oct 9. Glia. 2020. PMID: 31596526 - Inhibitors of NF-κB and P2X7/NLRP3/Caspase 1 pathway in microglia: Novel therapeutic opportunities in neuroinflammation induced early-stage Alzheimer's disease.
Thawkar BS, Kaur G. Thawkar BS, et al. J Neuroimmunol. 2019 Jan 15;326:62-74. doi: 10.1016/j.jneuroim.2018.11.010. Epub 2018 Nov 20. J Neuroimmunol. 2019. PMID: 30502599 Review. - Targeting the microglial NLRP3 inflammasome and its role in Parkinson's disease.
Haque ME, Akther M, Jakaria M, Kim IS, Azam S, Choi DK. Haque ME, et al. Mov Disord. 2020 Jan;35(1):20-33. doi: 10.1002/mds.27874. Epub 2019 Nov 4. Mov Disord. 2020. PMID: 31680318 Review.
Cited by
- Inflammasomes in neurological disorders - mechanisms and therapeutic potential.
Ravichandran KA, Heneka MT. Ravichandran KA, et al. Nat Rev Neurol. 2024 Feb;20(2):67-83. doi: 10.1038/s41582-023-00915-x. Epub 2024 Jan 9. Nat Rev Neurol. 2024. PMID: 38195712 Review. - Identification of Genetic Modifiers of TDP-43: Inflammatory Activation of Astrocytes for Neuroinflammation.
Kim JH, Rahman MH, Park D, Jo M, Kim HJ, Suk K. Kim JH, et al. Cells. 2021 Mar 18;10(3):676. doi: 10.3390/cells10030676. Cells. 2021. PMID: 33803845 Free PMC article. - Neuroimmune connections between corticotropin-releasing hormone and mast cells: novel strategies for the treatment of neurodegenerative diseases.
Bhuiyan P, Wang YW, Sha HH, Dong HQ, Qian YN. Bhuiyan P, et al. Neural Regen Res. 2021 Nov;16(11):2184-2197. doi: 10.4103/1673-5374.310608. Neural Regen Res. 2021. PMID: 33818491 Free PMC article. Review. - Research advances in cGAS-stimulator of interferon genes pathway and central nervous system diseases: Focus on new therapeutic approaches.
Ding J, Dai Y, Zhu J, Fan X, Zhang H, Tang B. Ding J, et al. Front Mol Neurosci. 2022 Dec 22;15:1050837. doi: 10.3389/fnmol.2022.1050837. eCollection 2022. Front Mol Neurosci. 2022. PMID: 36618820 Free PMC article. Review. - The role of inflammation in neurodegeneration: novel insights into the role of the immune system in C9orf72 HRE-mediated ALS/FTD.
Masrori P, Beckers J, Gossye H, Van Damme P. Masrori P, et al. Mol Neurodegener. 2022 Mar 18;17(1):22. doi: 10.1186/s13024-022-00525-z. Mol Neurodegener. 2022. PMID: 35303907 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous